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ABSTRACT: Amphiphilic cyclodextrin (ACyD) provides water-
soluble and adaptable nanovectors by modulating the balance
between the hydrophobic and hydrophilic chains at both CyD
sides. This work aimed to design nanoassemblies based on
nonionic and hydrophilic ACyD (SC6OH) for the delivery of a
poor-water-soluble organotin(IV)-porphyrin derivative
[(Bu3Sn)4TPPS] to melanoma cancer cells. To characterize the
porphyrin derivatives under simulated physiological conditions, a
speciation was performed using complementary techniques. In
aqueous solution (≤20 μM), (Bu3Sn)4TPPS primarily exists as a
monomer (2 in Figure 1), as suggested by the low static
anisotropy (ρ ≈ 0.02) with a negligible formation of porphyrin
supramolecular aggregates. MALDI-TOF spectra indicate the
presence of moieties (i.e., [(Bu3Sn)3TPPS]
−) that are derivatives of the monomeric species. Spectroﬂuorimetry coupled with
potentiometric measurements primarily assesses the presence of the hydrolytic [(Bu3Sn)4TPPS (OH)4]
4− species under
physiological conditions. Nanoassemblies of (Bu3Sn)4TPPS/SC6OH were prepared by dispersion of organic ﬁlms in PBS at pH
7.4 and were investigated using a combination of spectroscopic and morphological techniques. The UV−vis and emission
ﬂuorescence spectra of the (Bu3Sn)4TPPS/SC6OH reveal shifts in the peculiar bands of the organotin(IV)-porphyrin derivative
due to its interaction with the ACyD supramolecular assemblies in aqueous solution. The mean size was within the range of
100−120 nm. The ξ-potential was negative (−16 mV) for the (Bu3Sn)4TPPS/SC6OH nanoassemblies, with an entrapment
eﬃciency of approximately 67%. The intracellular delivery, cytotoxicity, nuclear morphology and cell growth kinetics were
evaluated via ﬂuorescence microscopy on A375 human melanoma cells. The delivery of (Bu3Sn)4TPPS by ACyD with respect to
free (Bu3Sn)4TPPS increases the internalization eﬃciency and cytotoxicity to induce apoptotic cell death and, at lower
concentrations, changes the cellular morphology and prevents cell proliferation.
■ INTRODUCTION
Amphiphilic cyclodextrins (ACyD) form established nano-
architectures for drug delivery.1 Nanoassemblies based on
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ACyD substituted with thioalkyl and oligoethylen glycol chains
at the primary and secondary rims of the CyD cavity, respectively,
have generated great interest because they can form diﬀerent
nanostructures (such as micelles, micellar clusters, vesicles and
nanoparticles) in aqueous solution, depending on both the
hydrophobic−hydrophilic balance and the charge of the
amphiphile.2,3 In vitro, these supramolecular systems are capable
of entrapping and delivering conventional anticancer drugs,4
photosensitizers,5,6 metal nanoparticles,7 or combined doses of
phototherapeutics for dual action.8,9 Moreover, the cationic
analogues of these ACyD3 have been proposed as nonviral agents
for gene therapy analogous to other nanocomplexes based on
CyD.10 Unlike other ACyD-based systems,1 these assemblies are
particularly stable in aqueous and physiological media, and those
substituted with short thioalkyl chains (-SCnHn+1, n ≤ 6) form
homogeneous and clear dispersions upon visual inspection (with
average sizes of ∼80 nm). Covalent modiﬁcations with receptor
targeting groups11 and ﬂuorophoric labels12 confer a high
potential for targeted drug delivery and drug monitoring,
respectively. The versatility of drug encapsulation in nonionic
ACyD nanoassemblies is primarily due to the presence of a
thioalkyl-chain-based inner hydrophobic portion, an external
hydrophilic region and the macrocycle cavity (Scheme 1), which
enable the design of various types of ACyD supramolecular
nanocomplexes with diﬀerent therapeutically important lip-
ophilic or hydrophilic guests.5,13−15 Generally, ACyD nano-
carriers have sizes compatible with IV injection and have been
proposed for optimizing anticancer drug distribution in the body
through their potential to extravasate at the level of the tumor
defective capillary bed and to deliver the drug to the site of
action.4,16,17 Therefore, the therapeutic approaches using ACyD
nanoassemblies are promising for a large number of diseases,
including resistant forms of cancer such as melanoma. Recent
investigations in this area have focused on the use of
Figure 1.Molecular formulas of coordination polymer 1 (A, B), as characterized at the solid state40 and of monomer 2 (C) plausibly formed in solution
(e.g., both 2 and derivative species of 2 have been detected in coordinating solvent as DMSO, EtOH, and up to 20 μM in H2O).
Scheme 1. Sketched View of Nanoassemblies Formation in
Aqueous Solution from SC6OH and (Bu3Sn)4TPPS
a
aIn H2O, (Bu3Sn)4TPPS is plausibly entrapped as derivative species of
2 (i.e., [(Bu3Sn)4TPPS (OH)4]
4− is the most probable at pH = 7.4 as
ascertained by speciation, see Figure 2).
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polymers,18,19 protein-targeted liposomes,20 and CyD-based
nanoparticles as delivery agents for tumor treatment.21,22
Melanoma is the most deadly form of skin cancer and is largely
refractory to existing therapies. Over the last thirty years, the
worldwide incidence of melanoma has steadily increased more
rapidly than that of any other malignancy.23,24 The detection and
surgical treatment of early stage disease appear to prevent
progression in most cases. However, patients with deep primary
tumors or tumors that metastasize to regional lymph nodes
frequently develop distant metastases.
Currently, the therapies for patients with metastatic malignant
melanoma include chemo- or immunotherapy or a combination
of the two.25−29 However, in the majority of cases, these
therapies are insuﬃcient because they can be limited and
noncurative.
Another therapeutic approach to melanoma has been
photodynamic therapy (PDT), which has been established for
certain types of cancer such as lung, esophageal, genitourinary,
head, and neck.30,31The PDT uses photosensitizing agents,
typically porphyrinoids, which can selectively enter and locate
tumors, generating radical oxygen species upon light activation.32
However, this therapy is weakly eﬀective for melanoma due to
long-term skin photosensitivity and the loss of absorbance during
irradiation caused by rapid photobleaching. Moreover, melanin,
the pigment produced by melanoma cells, absorbs light in the
same wavelength region (400−750 nm) as porphyrinoids, thus,
diminishing the photosensitizer eﬀect.33,34
Recently, the cytotoxic eﬀects of certain diorganotin(IV) and
triorganotin(IV)-meso-tetra(4-sulfonatophenyl) porphine deriv-
atives [(R2Sn)2TPPS and (R3Sn)4TPPS (R = Me, Bu)] were
tested on the A375 human melanoma cell line, and of these,
(Bu2Sn)2TPPS and (Bu3Sn)4TPPS exhibited high photo-
independent cytotoxicity.35 In particular, (Bu3Sn)4TPPS blocked
melanoma cell proliferation and induced changes in the cellular
morphology when used at low concentrations, suggesting cell
reprogramming toward a diﬀerentiated state.36,37
Although the poor water solubility of these porphyrins is
highly beneﬁcial in increasing the tumor-to-normal tissue ratio,38
as with highly lipophilic chemotherapeutic agents, it signiﬁcantly
limits intravenous administration.
The poor water solubility of (Bu3Sn)4TPPS (≤20 μM) and the
idea of more selectively targeting the melanoma cells led us to
entrap this compound in ACyD nanoassemblies based on short-
thioalkyl-substituted nonionic amphiphilic cyclodextrin
(SC6OH, Scheme 1). We ﬁrst demonstrate the ability of the
SC6OH nanoassemblies to both encapsulate the (Bu3Sn)4TPPS
and sustain its release under physiological conditions, delivering
this drug into highly metastatic A375 cells. Moreover, we
demonstrate that (Bu3Sn)4TPPS-loaded SC6OH (Scheme 1) is
more eﬀective than the free compound when used at the same
concentration. The (Bu3Sn)4TPPS/SC6OH nanoassemblies
induce the apoptosis of A375 melanoma cells or, when used at
lower concentrations, change the cellular morphology and arrest
cell proliferation.
■ MATERIALS AND METHODS
General Remarks. All solvents were puriﬁed and dried using
standard techniques. All other reagents were of the highest commercial
grade available and were used as received or were puriﬁed via distillation
or recrystallization when necessary. All solutions used for spectroscopic
characterizations were prepared in pure microﬁltered water (Galenica
Senese, Siena, Italy) and analyzed at 298 K. The heptakis(2-O-
oligo(ethylene oxide)-6-hexylthio)-β-CD (SC6OH, MWn=2 = 2763
amu.)39 and 140 (formula weight FW = 2091) were synthesized
according to the general procedures. Brieﬂy, 1 ((Bu3Sn)4TPPS, Bu3Sn
+
= [tributyltin(IV)+], TPPS4− = [meso-tetra(4-sulfonatophenyl)-
porphinate]4−) was obtained as a dark green solid by reﬂuxing
methanolic suspensions of (Bu3Sn)2O (Fluka-Riedel-de Haen,
Sigma−Aldrich Company, St. Louis, MO, U.S.A.) and free meso-
tetra(4-sulfonatophenyl) porphine (Porphyrin Products, Logan, UT,
U.S.A.). The solids, recovered via ﬁltration, were recrystallized from
methanol or methanol−ether solutions. The formal (Bu3Sn)4TPPS
concentrations (conveniently expressed in mol L−1 (M)) were
calculated using the FW of the repetitive unit (FW = 2091 amu). The
molar extinction coeﬃcients (ε) in DMSO, ethanol, and H2O were
measured via UV−vis spectroscopy (Lambert and Beer) by dissolving
(Bu3Sn)4TPPS (1.5−7 μM) in the various solvents.
UV−vis, Fluorescence and NMR Investigations. The UV−vis
absorption spectra were collected on a Hewlett-Packard model 8453
diode array spectrophotometer using 1 cm path length quartz cells.
Steady-state ﬂuorescence measurements were performed on a Jasco
model FP-750 spectroﬂuorimeter. Emission spectra were collected
using an excitation wavelength of 516 nm in a 1 cm path length quartz
cell. The depolarized ﬂuorescence spectra were measured using41
ρ = −
+
I I I I
I I I I2
VV HH VH HV
VV HH VH HV (1)
where ρ is the static anisotropy and IVV, IHH, IVH, and IHV are the
ﬂuorescence intensities registered with diﬀerent polarizer orientations
(V = vertical, H = horizontal).
The 1H NMR in DMSO-d6 was recorded on a Varian 500 MHz
spectrometer.
Speciation Studies. Spectroﬂuorimetric and Potentiometric
Titrations. The speciation of (Bu3Sn)4TPPS in pure microﬁltered
water was investigated using titrations in a Horiba Jobin-Yvon
Fluoromax-4 spectroﬂuorometer equipped with an F-3006 autotitration
injector with a Hamilton syringe (mods. Gastight 1725, 250-μL
capacity). Aliquots of the (Bu3Sn)4TPPS at various concentrations (up
to 1.7 μM) were prepared by diluting 17 μM stock aqueous solutions,
which were prepared by evaporating a measured volume of an ethanolic
solution ([(Bu3Sn)4TPPS] = 65 μM) and dissolving the organic ﬁlm in
water, followed by slight sonication. The porphyrin concentration was
measured via UV−vis using εH2O. The spectroﬂuorimetric titrations were
performed in the pH range of 3.7−10.1 at λexc = 516 nm, while the
emission spectra were collected at λem = 550−800 nm; the interval
between two titrant additions was 180 s. Simultaneous UV−vis titrations
in the same pH range and under the same conditions were performed to
assign the emitting species. The potentiometric and spectroscopic data
were processed using the Hyperquad 2008 program.42 The objective
function is given inmatrix notation simply asU = rWr, where r is a vector
of residuals (r = yobserved − ycalculated); here, yobserved represents a
measurement in mV, pH, or absorbance, and W is a matrix of weights.
For reﬁnement, the program minimizes the sum of squares of the
residuals relative to the diﬀerent variables. The residuals are ordered
with the potentiometric ﬁrst and the absorbance second. To minimize
the objective function, the Gauss−Newton-Marquardt method was
used. Diﬀerent mass-balance equations were deﬁned for each
component and were solved using the Newton−Raphson method; the
normal equation matrix was used to derive ∂[H]/∂βk, where βk is the
stability constant of the kth species and [H] is the free proton
concentration. More details are provided in the literature.42
The following stability constants were input into the speciationmodel
for the diacid species, protonated at the pyrroles of the porphyrinic ring
(log KH = 4.9),43,44 and the hydrolytic species of Bu3Sn
+(IV) (log βMH−1
= −6.13; log βMH−2 = −12.4).
45 The stability constants refer to the
general equilibria.
logKH: L +H = LH; log βMH−i: M + iH2O =MH−i + iH
+, where H−1 =
OH−; M = Bu3Sn
+; L = TPPS4−.
MALDI-TOF Mass Spectrometry. The negative MALDI-TOF mass
spectra were collected using a thin-layer deposition technique46,47 on a
Voyager-DE workstation (PerSeptive Biosystem), which utilizes a delay
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extraction procedure (25 kV applied after 2600 ns with a potential
gradient of 454 Vmm−1 and a wire voltage of 25 V) with ion detection in
the linear mode. The apparatus was equipped with a nitrogen laser
(emission at 337 nm for 3 ns) and a ﬂash AD converter (time base of 2
ns).
Nanoassembl ies . Preparat ion . Nanoassembl i e s o f
(Bu3Sn)4TPPS/SC6OH were prepared at 1:5 and 1:10 molar ratios
([(Bu3Sn)4TPPS] = 5 μM) according to previously reported
procedures.48 An organic ﬁlm was dosed by mixing and evaporating
aliquots of SC6OH and (Bu3Sn)4TPPS stock solutions. To yield 1:5 and
1:10 molar ratios, 150 μL of (Bu3Sn)4TPPS stock solution in EtOH (65
μM) was mixed with 24 and 48 μL of SC6OH stock solutions in CH2Cl2
(2060 μM), respectively. The organic ﬁlm was dispersed at T = 50 °C in
10 mMPBS at pH 7.4 or in H2O as speciﬁed and sonicated for 20 min in
an ultrasonic bath.
Particle Size Analysis. The mean diameter (size) and width of the
distribution (polydispersity index, PDI) of the SC6OH and
(Bu3Sn)4TPPS/SC6OH nanoassemblies, respectively, were determined
via photon correlation spectroscopy (PCS) using a Zetasizer Nano ZS
(Malvern Instruments, Malvern, U.K.) that utilizes noninvasive
backscattering (NIBS). The measurements were performed at a 173°
angle with respect to the incident beam and at 25 °C for each dispersion
of SC6OH and (Bu3Sn)4TPPS/SC6OH nanoassemblies using
bidistilled water or a 0.9 wt % NaCl aqueous solution as the dispersing
media. Each dispersion was stored in a cuvette and analyzed in triplicate.
The values reported were the averages of three measurements. The
deconvolution of the measured correlation curve to an intensity size
distribution was accomplished using a non-negative least-squares
algorithm.
ζ-Potential Measurements. The ζ-potentials were measured using
the principles of laser Doppler velocimetry and phase analysis light
scattering (an M3-PALS technique) on a Zetasizer Nano ZS Malvern
instrument. Empty SC6OH and (Bu3Sn)4TPPS/SC6OH nanoassem-
blies were dispersed in bidistilled water or in a 0.9 wt % NaCl aqueous
solution with the conductivity adjusted to 50 mS/cm. The results are
reported as the mean of three separate measurements on three diﬀerent
batches ± the standard deviation (SD).
Porphyrin Release Kinetics. An isotonic aqueous solution (PBS, 20
mM, pH 7.4) was used to obtain a release proﬁle of the porphyrin from
the (Bu3Sn)4TPPS/SC6OH nanoassemblies at a 1:5 porphyrin/
cyclodextrin molar ratio. The quantity of (Bu3Sn)4TPPS released was
determined via UV spectroscopy (UV-1800 spectrophotometer,
Shimadzu, Japan) at 413 nm. Brieﬂy, 2.0 mL aqueous (Bu3Sn)4TPPS/
SC6OH ([(Bu3Sn)4TPPS] = 50 μM)was introduced into a dialysis tube
(MWCO 5 KDa) and immersed in 25 mL of preheated medium (PBS,
20 mM, pH 7.4) at 37 ± 0.1 °C under continuous stirring in a Benchtop
80 °C incubator Orbital Shaker (model 420). At scheduled intervals,
solution aliquots (1 mL) were collected from outside the dialysis
membrane and replaced with fresh PBS. The release proﬁles were
determined by comparing the quantity of (Bu3Sn)4TPPS released as a
function of incubation time with the total quantity of drug loaded into
the SC6OH. The data were corrected by considering the dilution
procedure. A control experiment was also performed to determine the
release behavior of the free (Bu3Sn)4TPPS. A suspension of free
(Bu3Sn)4TPPS in PBS at pH 7.4 was prepared at the same concentration
(50 μM) as the drug entrapped in the (Bu3Sn)4TPPS/SC6OH
nanoassemblies. This suspension was placed in a dialysis tube
(MWCO 5 KDa) and immersed into the appropriate medium. The
amount of (Bu3Sn)4TPPS was determined as previously reported.
(Bu3Sn)4TPPS Encapsulation Eﬃciency. The (Bu3Sn)4TPPS loading
in the SC6OH and the encapsulation eﬃciency were assessed by
dissolving 1 mg freeze-dried SC6OH nanoparticles in 2 mL of THF and
evaluating the UV−vis absorption of the solution at 414 nm (UV-1800
spectrophotometer, Shimadzu, Japan). To verify the possible interfer-
ence of SC6OH, unloaded nanoparticles were dissolved in the THF. No
UV absorption was detected at 414 nm. The linearity of the UV response
was veriﬁed in the concentration range of 0.5−50 μg/mL (R2 = 0.985,
LOD = 0.04 μg/mL, LOQ = 0.20 μg/mL). The results are expressed as
the actual loading percentage (L.C., mg of drug encapsulated per 100mg
of nanoparticles) and the encapsulation eﬃciency (EE, the ratio of actual
to theoretical loading).
Biological Studies. Cell Culture. The A375 melanoma cell line is a
highly invasive cell line from a solid metastatic tumor (ATCC-CRL-
1619).49 The cells were cultured in RPMI supplemented with 10% heat-
inactivated fetal calf serum (FCS) and 1% penicillin-streptomycin
(10000 U/mL and 10000 μg/mL, respectively) in 5% CO2 at 37 °C.
Fluorescence Microscopy Analysis. Cells (4 × 104 cells/well in 400
μL growth medium) were plated on an 8-well Lab-Tek II chamber slide,
cultured for 24 h, and treated for 2 or 24 h, depending on the type of
experiment, with aqueous dispersions of (Bu3Sn)4TPPS/SC6OH at a
1:5 molar ratio [(Bu3Sn)4TPPS] = 5 or 0.25 μM and with SC6OH or
free (Bu3Sn)4TPPS. After incubation, the cells were ﬁxed as previously
described,37 and the nuclei were stained with Hoechst 33342 ﬂuorescent
DNA-binding dye at 0.01 mg/mL at room temperature for 10 min.
Fluorescence images were recorded using a digital camera system with a
rhodamine ﬁlter (red emission) to detect cellular localization of the
(Bu3Sn)4TPPS and a DAPI ﬁlter (blue emission) for Hoechst on a Zeiss
Axioskop 2 Plus microscope equipped for epiﬂuorescence.
Cell Death Assay. Cell death was evaluated using trypan blue 0.5%
(w/v; EuroClone), the stain most commonly used to distinguish viable
from nonviable cells. In brief, cells were plated into 12-well plates at 1.5
× 105 cells/well in 1.5 mL of growth medium. The cells were incubated
for 24 h and then treated with an aqueous dispersion of free
(Bu3Sn)4TPPS, (Bu3Sn)4TPPS/SC6OH at two diﬀerent
(Bu3Sn)4TPPS doses (0.5 or 0.25 μM), or unloaded SC6OH at
corresponding doses of 2.5 or 1.25 μM. The adherent and nonadherent
cells were pooled after 24, 48, and 72 h, and a small sample of each cell
suspension was diluted to 1:1 in trypan blue and counted under normal
light microscopy. The eﬀects of the treatment were quantiﬁed as the
percentage of cell death versus the untreated cells as a control.
Cell Growth Kinetics and Microscopic Digital Imaging. To
determine the growth curves, the cells were grown for 24 h in 12-well
plates at 1.5 × 105 cells/well in 1.5 mL of growth medium and then
treated with unloaded 0.75 μMSC6OH, 0.15 μM free (Bu3Sn)4TPPS or
(Bu3Sn)4TPPS/SC6OH [(Bu3Sn)4TPPS] = 0.15 μM and [SC6OH] =
0.75 μM. The cells were counted every 24 h for 72 h using the trypan
blue exclusion test. For Nomarski microscopic images, the cells (4× 104
cells/well in 400 μL growth medium) were plated on an 8-well Lab-Tek
II chamber slide, cultured for 24 h, and treated as previously described.
After each incubation, the cells were ﬁxed, and the nuclei were stained
with Hoechst 33342. Images were acquired with a Zeiss Axioskop 2 Plus
microscope.
■ RESULTS
Porphyrin Tributyltin(IV) Derivative in Solution. The
Bu3Sn(IV)
+ derivative of porphyrin (1) was synthesized as
reported in the literature40 and was isolated in the solid state as a
coordination polymer (Figure 1A). Analogously, 1 can be
sketched with the formula presented in Figure 1B, which depicts
a porphyrinoid moiety of the polymer.
Species 1 was dissolved in DMSO, EtOH, and H2O and was
characterized via UV−vis, steady-state ﬂuorescence, and
measurements of anisotropy in various solvents (see Supporting
Information, Figure 2A,B). The results are summarized in Table
1.
Species 1 is highly soluble in coordinating solvents such as
DMSO and EtOH (>50 μM), but less soluble in H2O (≤20 μM).
In DMSO, 1 exhibits a much higher molar extinction coeﬃcient
than in EtOH or H2O, in the range of 1.5−7 μM (εDMSO ≈ 4.2 ×
105 > εEtOH ≈ 3.5 × 105 ≈ εH2O ≈ 3.4 × 10
5 cm−1 M−1). The
average static anisotropy (ρ) is ∼0.02 for 1 dissolved in DMSO,
EtOH, and H2O (see Supporting Information, Figure 2B). The
1H NMR spectrum of 1 in DMSO-d6 (Supporting Information,
Figure 1) reveal the typical signals of porphyrin and tributyl
chains, which integrate for one porphyrin core (TPPS4−)
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coordinating to four tributyl tin units (Bu3Sn
+)4 (species 2 in
Figure 1C).
The speciation studies of 1 in aqueous solution were
performed using spectroﬂuorimetric and potentiometric titra-
tions and MALDI. The spectroﬂuorimetric spectra (see
Supporting Information, Figure 3) were analyzed together with
the potentiometric data using the Hyperquad 200842 program,
which enabled us to calculate the stability constants and
ﬂuorescence emission spectrum of each species using the
experimental ﬂuorescence intensities, the analytical concen-
trations of the reagents and the proposed chemical model as
inputs. The emitting species were assigned via UV−vis (data not
provided). The diﬀerent speciation models were evaluated;
however, the best outcomes were obtained when only the M4L
and M4L(OH)4 species (the charges are omitted for simplicity)
were considered.
The elaboration of the instrumental data (spectroﬂuorometric
and potentiometric) enabled us to obtain the following overall
stability constants for aqueous solutions of 1: log βM4L = 21.48 ±
0.09 and log βM4L(OH)4 = 3.66 ± 0.06 (the errors are reported as
±SD). The goodness of the adopted procedures for the
speciation studies and of the obtained results, can be highlighted
both from the low errors values associated to the overall stability
constants of the M4L and M4L(OH)4 species, as well as from the
statistical parameters of the titrations. In fact, independent of the
titration taken into account, the elaboration of the experimental
data (potentiometric and spectroﬂuorimetric) with the Hyper-
quad program,42 converged always within four iterations, with σ
(±SD on the ﬁt) values less than 800, a very low value if we
consider the ﬂuorescence emission relative intensities. Moreover,
the residuals observed between the experimental and calculated
ﬂuorescence intensity values were always, less than 4% for each
titration point.
The equilibria that refer to the log βM4L(OH)i (for OH
−, i = 0 or
4) species can also be expressed as stepwise stability constants.
For the M4L species, we can assume the equilibriumM(i−1)L +M
= MiL and calculate a mean stability constant of approximately
5.4 for each individual interaction between the metal ion
fragment Bu3Sn
+ and the sulfonic group. For the M4L(OH)4
species, we can consider the equilibrium 4MOH + L =
M4L(OH)4, which has a mean stepwise stability constant of
approximately 7.0. During the experimental data processing, the
formation of other species was examined; however, they were
systematically rejected by the computer program or their
formation percentages under these experimental conditions
were negligible, so they were considered minor species.
Figure 2 presents a distribution diagram of the species drawn at
a ligand concentration of 1.7 μM. The formation of the M4L
species can be observed at pH values below 5.0, while, at
physiological pH, the most important species, derived from the
hydrolysis of M4L, is M4L(OH)4, which reaches approximately
75%. At higher pH values, the free TTPS4− (Lfree) species
becomes predominant, while amaximum of∼4% of theM(OH)2
species was formed at pH ∼ 6.5.
The negative MALDI-TOF spectrum (Figure 3) exhibits
signals atm/z 1800 (detected as M−) and at m/z 1514 (detected
as M−), which are ascribed to the anionic moieties
(Bu3Sn)3TPPS
− and (Bu3Sn)2(H or Na)TPPS
− and can be
explained by a cationic (Bu3Sn
+) moiety loss from species 2
during the MALDI desorption process. The inset of Figure 3
provides a comparison between the experimental isotopic cluster
peaks at m/z 1800 (detected as M−) and the simulated isotopic
distribution species (because of the isotopic composition,
molecular species are detected in the mass spectra as clusters
of peaks; to simplify their assignments, m/z values reported in
the text are referred to the ﬁrst peak of each cluster,
corresponding to the ion containing the most abundant isotope
of each element present).
Table 1. Spectroscopic Properties of 1: Molar Absorbitivity ε
and Anisotropy ρ Measured at the Wavelength of the
Absorbtion (λ) and Emission Maxima (λem), Respectively in
Various Solvents
solvent λ/nm (ε/Mol−1 cm−1)a λem/nm (ρ)
b
EtOH 416 (3.5 × 105) 650 (0.03)
716 (0.02)
DMSO 420 (4.2 × 105) 652 (0.03)
717 (0.02)
H2O 413 (3.4 × 10
5) 644 (0.01)
708 (0.04)
aStandard error was ≅3% in all the determinations (ﬁve samples were
analyzed at 1.5−7 μM concentration range). bλexc = 516 nm.
Figure 2. Distribution diagram of the species formed in 1 aqueous
solution at T = 37 °C ([1] = 1.7 μM; M = Bu3Sn
+; L = TPPS4−).
Figure 3. Negative MALDI-TOF mass spectrum of 1. In the inset, for
comparison, the experimental isotopic cluster peaks of (Bu3Sn)3TPPS
−
species (M−, continuous line) and its simulated isotopic distribution
(dotted line; fwhm = 1400) is reported.
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Porphyrin/ACyD Nanoassemblies. Scheme 1 presents an
approach for the formation of nanoassemblies of SC6OH and 1
in aqueous solution.
The complexation between the (Bu3Sn)4TPPS and SC6OH
was investigated via UV−vis and ﬂuorescence emission spec-
troscopy, both in aqueous solution and in PBS at pH 7.4. Figure
4A presents the UV−vis spectra in PBS. As in other studies,12 an
excess of cyclodextrin was used as the complexing agent. Free
(Bu3Sn)4TPPS exhibits a B-band centered at 414 nm, which is
red- shifted at 420 nm, exhibiting hypochromicity in the
(Bu3Sn)4TPPS/SC6OH complexes (at both the 1:5 and 1:10
molar ratios). A slight hyperchromicity was registered as the
carrier quantity increased from 1:5 to 1:10 porphyrin/cyclo-
dextrin molar ratios. In addition, the Q-band region of the
complexes reveals a small but detectable shift with respect to the
free porphyrin.
The ﬂuorescence emission bands of the free porphyrin
exhibited maxima at 644 and 707 nm, which shifted to 650 and
715 nm, respectively, in the (Bu3Sn)4TPPS/SC6OH nano-
assemblies (Figure 4B). At the lower drug/carrier molar ratio
(1:10), the absorbance of the peculiar bands appeared slightly
higher than at the higher porphyrin/cyclodextrin molar ratio
(1:5).
The properties of the free ACyD and porphyrin/ACyD
nanoassemblies (mean diameter, polydispersity index, and ζ-
potential) are reported in Table 2.
The SC6OH nanoassemblies exhibited a size distribution with
amean diameter of approximately 200 nm in water that increased
slightly in NaCl medium. In addition, the ζ-potential value was
approximately −6 mV in H2O and increased in 0.9 wt % NaCl
aqueous solution. The particle sizes diﬀered slightly for the free
SC6OH and (Bu3Sn)4TPPS/SC6OH nanoassemblies, with the
latter having a mean diameter of approximately 230 nm and a ζ-
potential of approximately −15 mV. These values increased in
aqueous NaCl, and all particle distributions remained narrow
(PDI values lower than 0.300).
Controlled Release Studies. The release proﬁles of the
(Bu3Sn)4TPPS species from the porphyrin/cyclodextrin nano-
assemblies in PBS at pH 7.4 were determined as reported in the
literature.50 The results are presented in Figure 5.
In the absence of ACyD, concentration equilibrium was
reached between the compartments inside and outside the
dialysis bag within 72 h. Moreover, under these conditions, we
observed that the release proﬁle was aﬀected by degradation
phenomena. In contrast, the release from the porphyrin-loaded
ACyD was signiﬁcantly delayed.
Biological Studies. Intracellular Delivery. To verify the
ability of A375 human melanoma cells to take up porphyrin
delivered via ACyD, these cells were treated for 2 h with either
free (Bu3Sn)4TPPS or (Bu3Sn)4TPPS/SC6OH nanoassemblies
with a porphyrin concentration of 5 μM. The intracellular
localization of the (Bu3Sn)4TPPS was revealed by its typical and
well-detectable red ﬂuorescence emission, as shown in Figure 6.
Nuclear staining of these cells with ﬂuorescent Hoechst dye
demonstrated that the porphyrin species enter into the nucleus
(Figure 6C4) and concentrate in the nucleoli (see arrows in
Figure 4. UV−vis spectra (A) and ﬂuorescence emission spectra, λexc =
516 nm (B) of (Bu3Sn)4TPPS (red trace), (Bu3Sn)4TPPS/SC6OH at
1:5 (blue trace) and 1:10 (black trace) molar ratio in PBS 10 mM (pH =
7.4, T = 25 °C). In all the dispersions [(Bu3Sn)4TPPS] was 5 μM.
Table 2. Properties of Nanoassemblies: Mean Diameter,
Polydispersity Index (PDI), Zeta Potential (ζ in Twice-
Distilled Water and in Aqueous Solution of NaCl 0.9 wt %a
sample
dispersing
medium
mean diameter
(nm) PDI
ζ (mV)
(±SD)
SC6OH H2O 206.71 0.261 −5.55
(±1.08)
NaCl 0.9% 224.42 0.282 −1.55
(±1.21)
(Bu3Sn)4TPPS/
SC6OHb,c,d
H2O 228.43 0.264 −15.3
(±2.50)
NaCl 0.9% 248.13 0.273 −6.08
(±1.15)
aStandard deviation (SD) was calculated on three diﬀerent batches.
b(Bu3Sn)4TPPS/SC6OH are at 1:5 molar ratio.
cActual loading (mg
of drug encapsulated per 100 mg of nanoparticles) was 0.20.
dEntrapment eﬃciency (ratio of actual to theoretical loading × 100)
was 67%.
Figure 5. Release proﬁle of (Bu3Sn)4TPPS from (Bu3Sn)4TPPS/
SC6OH nanoassemblies (red trace) and from free (Bu3Sn)4TPPS as
control (black trace) in PBS (20 mM) at pH 7.4, T = 37 °C). Each value
is the mean of three experiments ± SD.
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Figure 6C4). No clear ﬂuorescence signal was observed below 5
μM (Bu3Sn)4TPPS (data not presented). Even with the high
(Bu3Sn)4TPPS (free or with SC6OH) concentration used in this
experiment, after 2 h of treatment, the cells exhibited certain
morphological changes, although their nuclei and nucleoli
remained intact (Figures 6F,G,C4), most likely referring to an
early stage of apoptosis. Moreover, the unloaded SC6OH at the
same concentration of the nanocomplex (25 μM) does not
appear to induce cytotoxicity because the cells exhibited a normal
morphology (Figure 6D) similar to that of the untreated cells
(Figure 6A).
Apoptosis and Cell-Growth Arrest of A375Melanoma Cells.
To determine the eﬀectiveness of the porphyrin/ACyD
nanosystem, the cells were treated for 24, 48, and 72 h with
two doses of (Bu3Sn)4TPPS/SC6OH. At a dose of 0.5 μM, both
the free (Bu3Sn)4TPPS and nanoassemblies induced a similar
level of cell death, up 90−100%, thus, producing identical
cytotoxic eﬀects (data not provided). In contrast, a lower dose
(0.25 μM) of free (Bu3Sn)4TPPS produced signiﬁcantly less cell
death (no more than 30%), while the (Bu3Sn)4TPPS/SC6OH
nanoassemblies still produced a highly cytotoxic eﬀect on the
A375 cells, as shown in Figure 7.
To investigate which cell death process was induced, we
stained the cells with Hoechst dye to highlight the potential
apoptotic nuclei. As shown in Figure 8G, the nuclei of the cells
treated with the (Bu3Sn)4TPPS/SC6OH nanoassemblies
([(Bu3Sn)4TPPS] = 0.25 μM) exhibited morphological features
of apoptosis, revealing a brighter chromatin than the nuclei of the
untreated cells or the cells treated with free (Bu3Sn)4TPPS or
unloaded SC6OH. The chromatin formed crescent and ring-like
structures or, during the later stages of apoptosis, bright spherical
beads.
A further reduction in the nanoassembly dose with
(Bu3Sn)4TPPS at 0.15 μM did not aﬀect the cell death but did
arrest the A375 cell proliferation, especially after 48 h of
treatment. In contrast, no eﬀect was observed on cell growth with
free (Bu3Sn)4TPPS, regardless of treatment time (Figure 9).
The less proliﬁc behavior of the A375 cells was associated with
an evident morphological change at 48 and 72 h compared with
the cells treated with free (Bu3Sn)4TPPS or with unloaded
SC6OH. After 24 h of treatment with the (Bu3Sn)4TPPS/
SC6OH nanoassemblies ([(Bu3Sn)4TPPS] = 0.15 μM), the cells
began to lengthen (Figure 10B), exhibiting an increasingly
spindle-shaped phenotype with longer treatment time (Figure
10H,N). After 72 h, most of the cells appeared fusiform- and star-
shaped with the dendrite-like projections (Figure 10N) that are
characteristic of adult human melanocytes, that is, their primary
cells.
■ DISCUSSION
Advanced melanoma remains associated with an extremely poor
median survival and one of the most treatment-refractory
malignancies. Many agents have been investigated for antitumor
Figure 6. Intracellular delivery of (Bu3Sn)4TPPS into A375 human
melanoma cells by (Bu3Sn)4TPPS/SC6OH nanoassemblies at 1:5
molar ratio. Nomarski images (A−D); ﬂuorescence images by Hoechst
stain (E−H); ﬂuorescence images by porphyrin species (I−L).
Magniﬁed images of rectangle in C (C1) and merged images (C2−
C4). Cells were treated with (Bu3Sn)4TPPS ([(Bu3Sn)4TPPS] = 5 μM)
(B, F, J), (Bu3Sn)4TPPS/SC6OH ([(Bu3Sn)4TPPS] = 5 μM, [SC6OH]
= 25 μM) (C, G, K), or SC6OH ([SC6OH] = 25 μM) (D, H, L) for 2 h,
then ﬁxed and analyzed as described in Materials and Methods. Original
magniﬁcation 40×.
Figure 7. Cytotoxic eﬀects of (Bu3Sn)4TPPS/SC6OH on A375 human
melanoma cell viability. Cells were treated for 24, 48, and 72 h with
(Bu3Sn)4TPPS/SC6OH nanoassemblies at 1:5 molar ratio
([(Bu3Sn)4TPPS] = 0.25 μM, [SC6OH] = 1.25 μM), SC6OH
([SC6OH] = 1.25 μM), or free (Bu3Sn)4TPPS ([(Bu3Sn)4TPPS] =
0.25 μM). Cell death was evaluated by trypan blue assay, using untreated
cells as controls. Each data represent the percentage of cell death
calculated from at least three separate experiments, for which the
standard deviation is indicated.
Figure 8. Nuclear morphology of A375 melanoma cells treated with
(Bu3Sn)4TPPS/SC6OH. Nomarski images (A−D); ﬂuorescence
images by Hoechst stain (E−H). Cells were treated for 24 h with free
(Bu3Sn)4TPPS ([(Bu3Sn)4TPPS ] = 0.25 μM (B, F), (Bu3Sn)4TPPS/
SC6OH nanoassemblies at 1:5 molar ratio ([(Bu3Sn)4TPPS ] = 0.25
μM, [SC6OH] = 1.25 μM) (C, G), or SC6OH ([SC6OH] = 1.25 μM)
(D, H) and nuclei were observed after staining with ﬂuorescent dye
Hoechst 33342. Untreated cells were used as control (A, E).
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activity in melanoma; however, the current therapies have not
overcome the high chemo-resistance of this aggressive and
deadly malignancy. Thus, new therapeutic approaches to this
disease are urgently needed.
As demonstrated and conﬁrmed in this work, engineering
(Bu3Sn)4TPPS with a carrier as a supramolecular assembly
appears to be a good approach to realize a successful
nanotherapeutic, given its high eﬀectiveness and interesting
photo-independent eﬀects on the proliferation of highly
metastatic A375 melanoma cells. Moreover, previous studies
demonstrated that in A375 melanoma cells, the (Bu3Sn)4TPPS
compound decreases the expression of proteins involved in both
tumorigenesis51−53 and melanoma progression,54−56 such as β-
catenin, c-myc, and snail, suggesting a probable reversion of
tumor cells to a normal phenotype.36,37 Such proteins play a key
role in the epithelial-to-mesenchymal transition (EMT). The
EMT is an important developmental program by which cells
switch from a polarized epithelial phenotype to a highly motile
mesenchymal phenotype. In contrast, if stimulated within an
adult organism, the EMT process promotes pathological
conditions or tumor metastasis.57 Therefore, (Bu3Sn)4TPPS
may aﬀect the restoration of the reverse EMT program, the
mesenchymal-to-epithelial transition (MET), which could
reduce the dediﬀerentiation and dissemination of tumor cells.
In previous studies, the observed eﬀects were obtained at a
lower (Bu3Sn)4TPPS concentration than that used here;
however, the compound was dissolved in DMSO, which is
known to be an unsuitable environment for cells. This work
involved (Bu3Sn)4TPPS/SC6OH nanoassemblies in water to
yield the same eﬀects of (Bu3Sn)4TPPS at almost twice the
concentration, below which the drug had no eﬀect on melanoma
cells (data not presented).
To relate the strong eﬀect of the (Bu3Sn)4TPPS dosed in
DMSO on the typology of the active species in this solvent,
spectroscopic characterizations were performed. Even though a
quantitative speciation of 1 was not possible in this high-
coordinating solvent,58 the1H NMR spectra strongly suggested
the formation of 2 (see Figure 1), as indicated by the integrals of
the porphyrin signals (Supporting Information, Figure 1).
However, the sharpness of the signals excluded the presence of
oligomeric/polymeric species (e.g., derivatives species of 2). A
comparison of the spectroscopic properties of (Bu3Sn)4TPPS in
diﬀerent coordinating solvents, DMSO, EtOH, and H2O, helped
to determine a rationale for the biological activity of 1. The UV−
vis and ﬂuorescence emission spectra of 1 (Supporting
Information, Figure 2A,B), both in DMSO and EtOH, conﬁrmed
the low tendency of porphyrin to self-aggregate at the
investigated concentration (1.5−7 μM). This behavior is most
likely due to the coordinating eﬀect of the solvent on
tributyltin(IV),58 which destabilizes the formation of supra-
molecular porphyrin adducts and oligomeric species coordinated
by sulfonate groups at the periphery of the porphyrin.
Furthermore, the higher extinction values for 1 in DMSO
compared with those in EtOH, as reported in Table 1, rely on the
improved solvent properties of the DMSO. The static anisotropy
values for both the DMSO and ethanolic solutions of
(Bu3Sn)4TPPS are approximately 0.02, suggesting the presence
of free chromophoric species and the reduced presence of
oligomeric supramolecular porphryin aggregates or interacting
polymeric arrays.59 Therefore, in highly coordinating solvents
Figure 9. Eﬀects of (Bu3Sn)4TPPS/SC6OH on A375 cell proliferation.
Cells were treated with (Bu3Sn)4TPPS/SC6OH nanoassemblies at 1:5
molar ratio ([(Bu3Sn)4TPPS ] = 0.15 μM, [SC6OH] = 0.75 μM),
SC6OH ([SC6OH] = 0.75 μM), or free (Bu3Sn)4TPPS
([(Bu3Sn)4TPPS ] = 0.15 μM) for 24, 48, and 72 h, as described in
Materials and Methods. Cell numbers were evaluated by trypan blue
exclusion test at the end of treatments. Error bars represent the standard
deviation of three separate experiments.
Figure 10. Eﬀects of (Bu3Sn)4TPPS/SC6OHon A375 cell morphology.
Nomarski images (A−C; G−I; M−O); ﬂuorescence images by Hoechst
stain (D−F; J−L; P−R). Cells treated with (Bu3Sn)4TPPS/SC6OH
nanoassemblies ([(Bu3Sn)4TPPS ] = 0.15 μM, [SC6OH] = 0.75 μM)
(B, E, H, K, N, Q), SC6OH (C, F, I, L, O, R), or free (Bu3Sn)4TPPS (A,
D, G, J, M, P) were observed after 24, 48, and 72 h.
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(i.e., DMSO and EtOH), we propose the presence of monomeric
derivatives of 1 (i.e., 2 in Figure 1C) in the investigated
concentration range. In addition, in H2O, the UV and
ﬂuorescence emission spectra (Supporting Information, Figure
2A,B) and the anisotropy values agree with the formation of
monomers at least up to 7 μM. The spectroﬂuorimetric and
potentiometric titrations (see the distribution diagram in Figure
2) indicate the formation of both (Bu3Sn)4TPPS and
[(Bu3Sn)4TPPS(OH)4]
4−; the latter is the species with the
highest percentage formed (∼75%) under physiological
conditions.60,61 The stability constants of the M4L(OH)i (i = 0
or 4) species indicate that they are not strong complexes;
however, TPPS4− is able to avoid the hydrolysis of the alkyltin
cations over the entire pH range investigated, a fact that is
observable with a low percentage of M(OH)2 formation.
Due to the high number of degrees of freedom in the system
and the large number of data points collected, the low values of
the statistical parameters for the titrations can be considered
signiﬁcant at a 95% conﬁdence interval. Moreover, in this
speciation, the contribution of species derivatives from small
adducts of porphyrin was negligible at the investigated
concentration (∼2 μM). In addition, by simulating the
preparative conditions in aqueous solution, the MALDI-TOF
mass spectrometry investigations reveal the presence of the
trisubstituted fragment (Bu3Sn)3TPPS
− (detected as M−, see
Figure 3), which is derived frommonomer 2. In PBS, at pH = 7.4,
the UV−vis and ﬂuorescence emission spectra (Figure 4A,B)
agree with the behavior of free 1 in H2O (with the prevalent
formation of monomeric species 2). In PBS, at pH 7.4, the
complexation between the(Bu3Sn)4TPPS species (e.g., 2 and
hydroxyl derivatives of 2) and amphiphilic cyclodextrin was
evident in the shifts of the unique absorption and emission bands.
The pophyrin/ACyD nanoassemblies proved to be highly
stable in water and in the presence of NaCl (0.9 wt %) under
ionic strength conditions simulating a physiological medium (see
Table 2). Diﬀerences observed in either media for empty and
loaded cyclodextrins can likely be attributed to the dependency
between the ζ-potential and the type and concentration of ions
present in the aqueous medium and are strongly aﬀected by the
size and localization of the ions in the diﬀusive layer of each
nanoparticle.62,63 The absence of a burst release (Figure 5)
indicated that the loaded drug was most likely encapsulated
inside the nanoassemblies as supramolecular complexes with
ACyD. As with other polymeric core−shell nanosystems used
against A375 melanoma cells,64 these results clearly address the
selection of amphiphilic cyclodextrin to increase the beneﬁt to
the controlled release and protection via the degradation
phenomena of hydrophobic tributyltin(IV) porphyrin deriva-
tives. The entrapment of the (Bu3Sn)4TPPS in SC6OH nonionic
amphiphilic cyclodextrin allowed the optimization of this drug as
follows. First, the entrapment permits the availability of
(Bu3Sn)4TPPS in water, a more suitable environment for cells,
eliminating the possible toxic eﬀects of the DMSO currently used
in in vitro experiments. Second, the uptake/release via
complexation with ACyD into melanoma cells is eﬃcient, as
indicated by the high and speciﬁc cytotoxicity and conﬁrmed by
the absence of cellular eﬀects due to the unloaded SC6OH.
Third, delivery via SC6OH allows the use of low (Bu3Sn)4TPPS
concentrations to block A375 cell proliferation and induce a
change of the cell morphology. Additional investigation into the
eﬀects of (Bu3Sn)4TPPS on melanoma is needed; however, the
entrapment of this porphyrin derivative into ACyD oﬀers
promising and interesting results, providing new insight into
cancer research. In the near future, we aim to develop
(Bu3Sn)4TPPS/SC6OH nanoassemblies to target speciﬁc
markers expressed in melanoma cells and to validate the system
eﬃcacy in vivo using mouse xenograft models of human
melanoma cells.
■ CONCLUSIONS
The proper design of nanoassemblies with improved water
solubility based on complexes of the tributyltin(IV) derivative of
meso-tetra(4-sulfonatophenyl)porphine with nonionic amphi-
philic cyclodextrin allows species with high anticancer potential
to be delivered into A375 melanoma cells under physiological
conditions. Various instrumental techniques in aqueous solution
have identiﬁed these active species as monomer derivatives from
the (Bu3Sn)4TPPS coordination polymer. Speciation studies
highlight the formation of both (Bu3Sn)4TPPS and
[(Bu3Sn)4TPPS(OH)4]
4−, with the latter having the highest
percentage of formation (∼75%) under physiological conditions.
The cell uptake of monomeric tributyltin(IV) porphyrin
incorporated in ACyD is highly eﬃcient. Moreover, nano-
assemblies based on the tributyltin(IV) porphyrin derivative/
ACyD complexes generate higher cytotoxicity than the free
porphyrin derivative in water, inducing apoptotic cell death and,
at lower concentrations, blocking cell proliferation in association
with a change in cellular morphology.
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